SC
CYTK icon

Shay Capital’s Cytokinetics CYTK Stock Holding History

Shay Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,500
Closed -$1.46M – 399
2023
Q4 		$1.46M Buy
+17,500
New +$634K 0.29% 62

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Shay Capital's CYTK Position: Q1 2026 in Review

Shay Capital reduced its Cytokinetics (CYTK) stake by 8.7% in Q1 2026, selling an estimated $19.8K and leaving 3,275 shares worth $216K. The position accounts for 0.02% of the portfolio, ranked #379.

Shay Capital first reported a position in CYTK in Q4 2023 and has held it in 10 quarters since. The position peaked at $3.16M in Q4 2023. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Shay Capital held 3,275 shares of Cytokinetics worth $216K as of Q1 2026.
  • Shay Capital sold 311 Cytokinetics shares in Q1 2026, an estimated $19.8K.
  • Cytokinetics made up 0.02% of Shay Capital's portfolio in Q1 2026, its #379 holding.
  • Shay Capital first reported a position in Cytokinetics in Q4 2023 and has held it in 10 quarters since.
  • Shay Capital's Cytokinetics position peaked at $3.16M in Q4 2023.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Shay Capital's 13F filing for Q1 2026, filed 15 May 2026.